Deepak Pasi, MD
Interventional Cardiology · Raleigh, NCNPI 1215936398
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 156 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for interventional cardiology clinicians in NC, where the typical reported total is $5,390.
Across 156 payments — averaging $24.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$619
- Abiomed$444
- E.r. Squibb & Sons, L.L.C.$440
- AstraZeneca$321
- Novartis$315
- Esperion Therapeutics, Inc.$220
- plus $2K from 19 others
Across 8 payments — averaging $13,859 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim Pharma GmbH & Co.kg$75K
- Boehringer Ingelheim International GmbH$36K
What the payments were for
- Food & beverage$3,890100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 14 | $619 |
| Abiomed | 4 | $444 |
| E.r. Squibb & Sons, L.L.C. | 19 | $440 |
| AstraZeneca | 18 | $321 |
| Novartis | 19 | $315 |
| Esperion Therapeutics, Inc. | 12 | $220 |
| Medtronic | 3 | $192 |
| Boehringer Ingelheim | 8 | $173 |
| Amgen | 9 | $172 |
| Shockwave Medical, Inc | 2 | $169 |
| Pfizer | 8 | $155 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $102 |
| Irhythm Technologies, Inc. | 4 | $98 |
| Novo Nordisk | 4 | $86 |
| Bristol Myers Squibb | 4 | $82 |
| Johnson & Johnson | 4 | $67 |
| Impulse Dynamics (USA) Inc. | 3 | $62 |
| Sanofi-aventis U.S. LLC | 2 | $44 |
| Kestra Medical Technology Services, Inc. | 2 | $39 |
| Bridgebio Pharma, Inc. | 1 | $23 |
| Baxter Healthcare | 1 | $18 |
| Edwards Lifesciences | 1 | $18 |
| Chiesi USA, Inc. | 1 | $15 |
| Philips North America LLC | 1 | $12 |
| Bardy Diagnostics, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,890 in reported general payments places this provider in the 35th percentile of 180 interventional cardiology providers in North Carolina.
See all interventional cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,872 | $1,807,858 |
| Repatha SureclickEvolocumab | 410 | $424,144 |
| EntrestoSacubitril/Valsartan | 368 | $385,256 |
| XareltoRivaroxaban | 319 | $323,792 |
| JardianceEmpagliflozin | 164 | $144,069 |
| BrilintaTicagrelor | 122 | $89,619 |
| Praluent PenAlirocumab | 87 | $87,769 |
| Dofetilide | 239 | $48,315 |
| FarxigaDapagliflozin Propanediol | 33 | $32,400 |
| Metoprolol Succinate | 1,910 | $25,071 |
| CorlanorIvabradine Hcl | 28 | $22,595 |
| MultaqDronedarone Hcl | 12 | $20,558 |
| Ranolazine ErRanolazine | 244 | $19,216 |
| Repatha SyringeEvolocumab | 25 | $18,286 |
| Ezetimibe | 846 | $16,269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $155 | $1,807,8581,872 claims |
| NovartisEntresto | $315 | $385,256368 claims |
| Johnson & JohnsonXarelto | $67 | $323,792319 claims |
| Boehringer IngelheimJardiance | $173 | $144,069164 claims |
| AstraZenecaBrilinta, Farxiga, Crestor | $321 | $125,402168 claims |
| AmgenCorlanor | $172 | $22,59528 claims |
| Sanofi-aventis U.S. LLCMultaq | $44 | $20,55812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 180 interventional cardiology providers in North Carolina.
Other interventional cardiology in Raleigh
- Ravish SacharRaleigh$1.6M
- Robert JobeRaleigh$191K
- James ZidarRaleigh$57K
- Willis WuRaleigh$56K
- Islam OthmanRaleigh$50K
- Andrew SampsonRaleigh$48K
- Dwijesh PatelRaleigh$40K
- Siva KethaRaleigh$19K
- Mohit PasiRaleigh$16K
- George AdamsGarner$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.